We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
Read MoreHide Full Article
Astrazeneca (AZN - Free Report) closed the most recent trading day at $73.55, moving -1.17% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.94%. On the other hand, the Dow registered a gain of 0.75%, and the technology-centric Nasdaq increased by 1.52%.
Coming into today, shares of the pharmaceutical had gained 8.15% in the past month. In that same time, the Medical sector gained 4.95%, while the S&P 500 gained 1.67%.
Investors will be eagerly watching for the performance of Astrazeneca in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $1.11, marking a 12.12% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $14.03 billion, reflecting a 8.42% rise from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $4.49 per share and revenue of $57.68 billion, indicating changes of +9.25% and +6.67%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Astrazeneca. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.06% lower. Astrazeneca currently has a Zacks Rank of #3 (Hold).
Looking at its valuation, Astrazeneca is holding a Forward P/E ratio of 16.56. This signifies a discount in comparison to the average Forward P/E of 19.72 for its industry.
Meanwhile, AZN's PEG ratio is currently 1.36. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.45 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 78, this industry ranks in the top 32% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
Astrazeneca (AZN - Free Report) closed the most recent trading day at $73.55, moving -1.17% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.94%. On the other hand, the Dow registered a gain of 0.75%, and the technology-centric Nasdaq increased by 1.52%.
Coming into today, shares of the pharmaceutical had gained 8.15% in the past month. In that same time, the Medical sector gained 4.95%, while the S&P 500 gained 1.67%.
Investors will be eagerly watching for the performance of Astrazeneca in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of $1.11, marking a 12.12% rise compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $14.03 billion, reflecting a 8.42% rise from the equivalent quarter last year.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $4.49 per share and revenue of $57.68 billion, indicating changes of +9.25% and +6.67%, respectively, compared to the previous year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Astrazeneca. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 0.06% lower. Astrazeneca currently has a Zacks Rank of #3 (Hold).
Looking at its valuation, Astrazeneca is holding a Forward P/E ratio of 16.56. This signifies a discount in comparison to the average Forward P/E of 19.72 for its industry.
Meanwhile, AZN's PEG ratio is currently 1.36. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.45 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 78, this industry ranks in the top 32% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.